This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study (PLASMA)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Alkahest, Inc.
Information provided by (Responsible Party):
Sharon Sha, Stanford University
ClinicalTrials.gov Identifier:
NCT02256306
First received: September 25, 2014
Last updated: November 29, 2016
Last verified: November 2016
  Purpose
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Mild-To-Moderate Alzheimer's Disease

Condition Intervention
Mild-To-Moderate Alzheimer's Disease Alzheimer's Disease Other: Plasma

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study: Intravenously-Administered Plasma From Young Donors for Treatment of Mild-To-Moderate Alzheimer's Disease

Resource links provided by NLM:


Further study details as provided by Sharon Sha, Stanford University:

Primary Outcome Measures:
  • Number of participants with adverse events as a measure of safety and tolerability, and number of subjects who comply with the research protocol as a measure of feasibility. [ Time Frame: 9 weeks ]

Secondary Outcome Measures:
  • Change on the 13-item ADAS-Cog [ Time Frame: 9 weeks ]
  • Change on the Trail-Making Test [ Time Frame: 9 weeks ]
  • Change on the Clinical Dementia Rating scale Sum of Boxes (CDR-SB) [ Time Frame: 9 weeks ]
  • Change on the Functional Activities Questionnaire (FAQ) [ Time Frame: 9 weeks ]
  • Change on the Alzheimer's Disease Cooperative Study Activities of Daily Living Inventory (ADCS-ADL) [ Time Frame: 9 weeks ]
  • Change on the Geriatric Depression Scale [ Time Frame: 9 weeks ]
  • Change on the Neuropsychiatric Inventory Questionnaire (NPI-Q) [ Time Frame: 9 weeks ]

Other Outcome Measures:
  • Change in functional connectivity in the default mode network as assessed by resting state functional MRI [ Time Frame: 9 weeks ]
  • Compositional assessment of plasma using in vitro analytical methods. The goal is to assess plasma components that might be associated with aging and/or Alzheimer's disease [ Time Frame: 9 weeks ]
  • In vivo assessment of plasma samples to determine their potential histological effects on the hippocampus and their potential behavioral effects in animal models of cognition [ Time Frame: 9 weeks ]
  • Differential effect of therapy on above outcomes as a function of ApoE genotype [ Time Frame: 9 weeks ]

Estimated Enrollment: 18
Study Start Date: September 2014
Estimated Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Young Donor Plasma
Subjects will receive 1 unit of plasma, once weekly for 4 weeks.
Other: Plasma
1 unit of Plasma From Young Donors (Male, aged 30 or younger)

  Eligibility

Ages Eligible for Study:   50 Years to 90 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of probable Alzheimer's disease (NIA-AA criteria)
  • Mini-Mental State Examination (MMSE) score 12-24
  • Availability of a study partner who knows the patient well and is willing to accompany the subject to all trial visits, to participate in questionnaires and to complete daily journal assessments

Exclusion Criteria:

  • Pregnancy or unwilling to use adequate birth control method for duration of and 6 months beyond study participation
  • Positive for Hepatitis B, Hepatitis C or HIV at screening
  • Any other condition or situation that the investigator believes may interfere with the safety of the subject or the intent and conduct of the study
  • Related to medical history:

    • Stroke
    • Anaphylaxis
    • Prior adverse reaction to any human blood product
    • Any history of a blood coagulation disorder or hypercoagulability
    • Congestive heart failure
    • Uncontrolled hypertension
    • Renal failure
    • Prior intolerance to intravenous fluids
    • Recent history of uncontrolled atrial fibrillation
    • IgA deficiency (by history)
  • Related to medications or other treatments:

    • Any concurrent use of an anticoagulant therapy. Antiplatelet drugs (e.g., aspirin or clopidogrel) are acceptable
    • Initiation or change in the dosage of a cholinesterase inhibitor or memantine during the trial. A participant already on a cholinesterase inhibitor or memantine must be on a stable dose for at least one month prior to Screening
    • Concurrent participation in another treatment trial for Alzheimer's disease. If there was prior participation, the last dose of the investigational agent must have been at least 6 months prior to Screening
    • Treatment with any human blood product, including intravenous immunoglobulin, during the 6 months prior to Screening or during the trial
    • Concurrent daily treatment with benzodiazepines, typical or atypical antipsychotics, long-acting opioids, or other medications that, in the investigator's opinion, interfere with cognition. Intermittent treatment with short-acting benzodiazepines or atypical antipsychotics may be permitted, provided that no dose is administered within the 72 hours preceding any cognitive assessment
  • Related to magnetic resonance imaging:

    • Claustrophobia
    • Any metallic surgical implant, like a pacemaker or clip that is incompatible with 3T MRI.

Certain metallic implants like joint replacements may be permitted, provided that specific manufacturer specifications are available and that the device is known to be safe for 3T MRI.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02256306

Locations
United States, California
Stanford University
Stanford, California, United States, 94305
Sponsors and Collaborators
Stanford University
Alkahest, Inc.
  More Information

Responsible Party: Sharon Sha, Principle Investigator, Stanford University
ClinicalTrials.gov Identifier: NCT02256306     History of Changes
Other Study ID Numbers: 30350
Study First Received: September 25, 2014
Last Updated: November 29, 2016

Additional relevant MeSH terms:
Alzheimer Disease
Dementia
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Tauopathies
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders

ClinicalTrials.gov processed this record on August 17, 2017